Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus GATIFLOXACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus GATIFLOXACIN.
FLOXIN IN DEXTROSE 5% vs GATIFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Gatifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
400 mg intravenously every 12 hours.
400 mg orally or intravenously once daily
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Terminal elimination half-life 7-14 hours (mean ~10 hours in healthy adults); prolonged in renal impairment (up to 40 hours with CrCl <30 mL/min)
Clinical Note
moderateGatifloxacin + Digoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGatifloxacin + Digitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGatifloxacin + Deslanoside
"Gatifloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGatifloxacin + Acetyldigitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Primarily renal excretion (70-87% unchanged in urine) via glomerular filtration and tubular secretion; ~10% biliary/fecal
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic